Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Iacta Pharmaceuticals
AddedFeb 16, 2024
UpdatedJun 18, 2026
Iacta Pharmaceuticals

Iacta Pharmaceuticals

IACTA Pharmaceuticals: Innovating and advancing safe, effective eye care drugs to meet unmet needs.

HQ
Irvine, CA, US
Founded
2016
Overview
Compare
Fundraising
Employees

IACTA Pharmaceuticals focuses on innovating and advancing safe, effective eye care drugs to meet unmet needs. The company aims to significantly improve the efficacy and safety of existing ophthalmic treatments while developing new drugs to address various unmet medical needs in the eye care market.

IACTA Pharmaceuticals has made notable strides in the field of ophthalmology, contributing to advancements in eye care treatments. Their work is recognized for addressing critical gaps in the market, enhancing patient outcomes, and pushing the boundaries of current medical standards in eye care.

Iacta Pharmaceuticals - Similar Companies

Eye-Pharma logo

Eye-Pharma

Zhaoke Ophthalmology Pharmaceutical logo

Zhaoke Ophthalmology Pharmaceutical

Visiox logo

Visiox

visioxpharma.com

Iview Therapeutics logo

Iview Therapeutics

Ikaria logo

Ikaria

Accuitis logo

Accuitis

accuitis.com

EyeCyte logo

EyeCyte

eyecyte.com

Auxilius Pharma logo

Auxilius Pharma

auxiliuspharma.com

EyePoint logo

EyePoint

Ocular Science logo

Ocular Science

ocularscience.com

Ocumension Therapeutics logo

Ocumension Therapeutics

MediPrint Ophthalmics logo

MediPrint Ophthalmics

Aria Pharmaceuticals logo

Aria Pharmaceuticals

Hyperion DeFi logo

Hyperion DeFi

eyenovia.com

Manhattan Pharmaceuticals logo

Manhattan Pharmaceuticals

Iacta Pharmaceuticals - Quick Facts

Who are Iacta Pharmaceuticals' competitors?

Companies similar to Iacta Pharmaceuticals include Eye-Pharma, Zhaoke Ophthalmology Pharmaceutical, Visiox and Iview Therapeutics.

When was Iacta Pharmaceuticals founded?

Iacta Pharmaceuticals was founded in 2016.

Where is Iacta Pharmaceuticals' headquarters located?

Iacta Pharmaceuticals' headquarters is located in Irvine, CA, US.

When was Iacta Pharmaceuticals' last funding round?

Iacta Pharmaceuticals' most recent funding round was for $1M (USD) in October 2021.

How much has Iacta Pharmaceuticals raised to-date?

As of Oct 28, 2021, Iacta Pharmaceuticals has raised a total of $1M (USD).

How many employees does Iacta Pharmaceuticals have?

Iacta Pharmaceuticals has 12 employees as of Feb 4, 2024.

Iacta Pharmaceuticals - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Drugs
  • Eye Care
Tags
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 16 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 325000Chemical Manufacturing
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 325410Pharmaceutical and Medicine Manufacturing
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 2830Drugs
  • 8730Research, Development, And Testing Services
  • 2834Pharmaceutical Preparations
  • 8731Commercial Physical and Biological Research